Cargando…
Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients
BACKGROUND: Von Hippel-Lindau (VHL) disease is a rare oncological disease with an incidence of 1:36,000, and is characterized by the growth of different types of tumors: hemangioblastomas in the central nervous system (CNS) and retina, renal carcinoma, pheochromocytomas, pancreatic serous cystadenom...
Autores principales: | Albiñana, Virginia, Villar Gómez de las Heras, Karina, Serrano-Heras, Gemma, Segura, Tomás, Perona-Moratalla, Ana Belén, Mota-Pérez, Mercedes, de Campos, José María, Botella, Luisa María |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579575/ https://www.ncbi.nlm.nih.gov/pubmed/26394686 http://dx.doi.org/10.1186/s13023-015-0343-5 |
Ejemplares similares
-
Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial
por: González-Rodríguez, Beatriz, et al.
Publicado: (2019) -
Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease
por: Albiñana, Virginia, et al.
Publicado: (2017) -
The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease
por: Cuesta, A. M., et al.
Publicado: (2019) -
Resection of von Hippel Lindau Related Brainstem Hemangioblastoma
por: Maggio, Dominic, et al.
Publicado: (2019) -
Von Hippel-Lindau Syndrome: Diagnosis and Management of Hemangioblastoma and Pheochromocytoma
por: Vaganovs, P., et al.
Publicado: (2013)